https://www.selleckchem.com/pr....oducts/s-gsk1349572.
The patients' characteristics were similar among phases. Changes in eGFR were similar among phases, but the incidence of RD increased in phase III (phase I 228 [10.3%]; phase II 260 [11.4%]; phase III 296 [13.0%], = 0.02). However, the differences in incidences of RD were not statistically significant after adjusting for eGFR at baseline and age. The incidences of HD were also similar among phases (phase I 175 [13.2%]; phase II 171 [12.9%]; phase III 167 [12.2%], = 0.72). The CDSS implementation did not affect the incidence of re
Like
Comment
Share
